drugset
drugset / Trial / NCT00818415

Naproxen Sodium ER Pharmacokinetic Study

NCT00818415 ↗

Phase 1 Completed 32 enrolled Bayer
RandomizedCrossoverOpen-labelTreatment

Summary

To determine the pharmacokinetic profile of the investigational product following dosing under fed conditions.

Timeline

Start
2008-11
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Naproxen Small molecule 220 mg —
Subject Naproxen Small molecule 440 mg —
Subject Naproxen Small molecule 660 mg —

Indications

No indication recorded.